Exelon (Rivastigmine)
Cholinesterase inhibitor for Alzheimer's dementia
Exelon (rivastigmine) is a cholinesterase inhibitor prescribed for the treatment of mild to moderate Alzheimer's dementia. It works by blocking the enzymes that break down acetylcholine in the brain, thereby helping to improve memory, cognitive function, and the ability to perform daily activities. Exelon is available as oral capsules and transdermal patches.
Quick Facts
Key Takeaways
- Exelon contains rivastigmine, a dual-action cholinesterase inhibitor that blocks both acetylcholinesterase and butyrylcholinesterase to increase acetylcholine levels in the brain.
- It is approved for the symptomatic treatment of mild to moderate Alzheimer's dementia and does not cure or halt the progression of the underlying disease.
- Treatment should be started at a low dose (1.5 mg twice daily for capsules) and gradually increased to minimize gastrointestinal side effects such as nausea and vomiting.
- The transdermal patch formulation provides steady drug delivery and is associated with fewer gastrointestinal side effects compared to oral capsules.
- If treatment is interrupted for more than three days, the dose must be re-titrated from the lowest starting level under medical supervision.
What Is Exelon and What Is It Used For?
Exelon belongs to a class of medications known as cholinesterase inhibitors. The active substance, rivastigmine, works by blocking two key enzymes in the brain: acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). In patients with Alzheimer's disease, certain nerve cells in the brain progressively die, leading to reduced levels of the neurotransmitter acetylcholine — a chemical messenger essential for communication between nerve cells. By preventing the breakdown of acetylcholine, Exelon helps maintain higher levels of this neurotransmitter, which can improve cognitive function and the ability to carry out everyday tasks.
Alzheimer's disease is the most common form of dementia, accounting for approximately 60–70% of all dementia cases worldwide according to the World Health Organization (WHO). The disease is characterized by a progressive decline in memory, thinking, orientation, comprehension, learning capacity, language, and judgment. It predominantly affects people over the age of 65, although early-onset forms can occur in younger individuals.
Exelon is indicated for the treatment of adult patients with mild to moderately severe Alzheimer's dementia. Clinical trials have demonstrated that rivastigmine can provide modest but statistically significant improvements in cognitive function, global clinical impression, and activities of daily living when compared to placebo. The Cochrane Collaboration's systematic review of cholinesterase inhibitors confirmed that rivastigmine shows consistent benefits in cognition and global assessment for patients with mild to moderate Alzheimer's disease.
It is important to understand that Exelon is a symptomatic treatment — it does not cure Alzheimer's disease or reverse the underlying neurodegeneration. However, by temporarily boosting cholinergic neurotransmission, it may help patients maintain their cognitive abilities and independence for a longer period. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have both approved rivastigmine for this indication, and it is included in clinical practice guidelines issued by the American Academy of Neurology (AAN) and the National Institute for Health and Care Excellence (NICE).
Rivastigmine is unique among cholinesterase inhibitors in that it inhibits both AChE and BuChE. This dual mechanism may offer theoretical advantages, as butyrylcholinesterase activity increases in the brain as Alzheimer's disease progresses, while acetylcholinesterase activity may decrease. By targeting both enzymes, rivastigmine may provide more sustained cholinergic support as the disease advances.
What Should You Know Before Taking Exelon?
Contraindications
Exelon must not be used if you are allergic to rivastigmine or any of the other ingredients in the formulation. Additionally, patients with known hypersensitivity to carbamate derivatives should not take this medication, as rivastigmine is a carbamate-type compound and cross-reactivity may occur.
For patients using the transdermal patch formulation, Exelon must not be used if you experience a skin reaction at the application site that spreads beyond the patch area, if an intense local reaction develops (such as blistering, increasing skin inflammation, or swelling), or if such a reaction does not improve within 48 hours after patch removal. In these cases, discontinue use and consult your prescribing physician immediately.
Do not use Exelon if you have a known allergy to rivastigmine or carbamate derivatives. If you experience severe skin reactions with the patch formulation, discontinue use and seek medical attention immediately.
Warnings and Precautions
Several medical conditions require particular caution when using Exelon. Before starting treatment, discuss your complete medical history with your doctor, especially if any of the following apply:
- Heart conditions: Irregular or slow heartbeat (bradycardia), QTc prolongation, family history of QTc prolongation, torsades de pointes, or low blood levels of potassium or magnesium. Cholinesterase inhibitors can exacerbate cardiac conduction disturbances.
- Gastrointestinal conditions: Active or history of stomach ulcers. Rivastigmine increases gastric acid secretion, which may worsen ulcerative conditions.
- Urinary difficulties: Bladder outflow obstruction or other conditions causing difficulty urinating, as cholinergic stimulation may exacerbate urinary retention.
- Seizure history: Current or past epilepsy or seizure disorders, as cholinesterase inhibitors may lower the seizure threshold.
- Respiratory conditions: Asthma or severe chronic obstructive pulmonary disease (COPD), as increased cholinergic tone may worsen bronchospasm.
- Tremor: Existing tremor conditions may be aggravated by cholinesterase inhibitor therapy.
- Low body weight: Patients weighing less than 50 kg may be at higher risk for adverse effects, particularly gastrointestinal side effects, and may require more careful dose titration.
- Liver impairment: Hepatic dysfunction may alter drug metabolism and clearance, requiring closer monitoring during treatment.
If gastrointestinal side effects such as nausea, vomiting, or diarrhea occur and persist, dehydration may develop. This is particularly concerning in elderly patients who may already be at risk for fluid depletion. Ensure adequate fluid intake during treatment and contact your physician if symptoms are prolonged or severe.
If Exelon treatment is interrupted for more than three consecutive days, do not restart at the previous dose. Contact your doctor, as the dose will need to be re-titrated from the lowest starting level to reduce the risk of severe gastrointestinal side effects.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Exelon. The potential benefit of treatment must be weighed against the possible risks to the unborn child. Exelon should not be used during pregnancy unless clearly necessary and only under strict medical supervision.
Women who are breastfeeding should not use Exelon, as it is not known whether rivastigmine passes into human breast milk. If treatment is considered essential, breastfeeding should be discontinued.
Driving and Operating Machinery
Alzheimer's disease itself impairs the ability to drive and operate machinery. Exelon may additionally cause dizziness, drowsiness, fainting, and confusion, which can further compromise your ability to perform these tasks safely. Your doctor will advise whether it is safe for you to drive or operate machinery while taking this medication. Do not drive, use machines, or perform any activities requiring alertness if you experience these side effects.
Children and Adolescents
There is no relevant use of Exelon in the pediatric population for the treatment of Alzheimer's disease. This medication is intended exclusively for adult patients.
How Does Exelon Interact with Other Drugs?
Drug interactions are an important consideration when taking Exelon, particularly in elderly patients who often take multiple medications. Rivastigmine's cholinergic mechanism of action means it can potentially interact with several classes of drugs. Below is an overview of the most clinically significant interactions.
Major Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Metoclopramide | Pharmacodynamic — additive extrapyramidal effects | Concurrent use can cause rigidity, tremor, and extrapyramidal symptoms. Avoid combination. |
| Beta-blockers (e.g., atenolol, metoprolol) | Pharmacodynamic — additive bradycardic effect | Combined use may cause excessive slowing of heart rate (bradycardia), potentially leading to syncope or loss of consciousness. Monitor heart rate closely. |
| Succinylcholine-type muscle relaxants | Pharmacodynamic — enhanced neuromuscular blockade | Exelon may prolong the effects of succinylcholine during general anesthesia. Inform your anesthesiologist before any surgery. |
| QT-prolonging drugs | Pharmacodynamic — additive cardiac effects | Risk of cardiac arrhythmias including torsades de pointes. Exercise caution and monitor ECG when combining. |
Minor Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Anticholinergic agents (e.g., dicyclomine, scopolamine, meclizine) | Pharmacodynamic — opposing mechanisms | Anticholinergics counteract the effects of Exelon, potentially reducing its therapeutic benefit. Avoid unnecessary concurrent use. |
| Anti-Parkinsonian drugs (e.g., amantadine) | Pharmacodynamic — opposing mechanisms | May reduce the effectiveness of both medications. Monitor clinical response. |
| Antiemetics (e.g., diphenhydramine) | Pharmacodynamic — anticholinergic effect | Antihistamines with anticholinergic properties may reduce rivastigmine efficacy. Consider alternative antiemetics. |
| Other cholinesterase inhibitors (e.g., donepezil, galantamine) | Pharmacodynamic — additive cholinergic effects | Do not combine with other cholinesterase inhibitors. Excessive cholinergic stimulation may cause a cholinergic crisis. |
It is essential to inform your doctor about all medications you currently take, have recently taken, or plan to take — including over-the-counter drugs, herbal supplements, and vitamins. This allows your healthcare provider to identify and manage potential interactions before they become clinically significant.
If you are scheduled for surgery requiring general anesthesia, inform your surgeon and anesthesiologist that you are taking Exelon. Rivastigmine can enhance the effects of certain muscle relaxants used during anesthesia, particularly succinylcholine-type agents, which may lead to prolonged neuromuscular blockade.
What Is the Correct Dosage of Exelon?
Exelon dosing follows a gradual titration approach to minimize gastrointestinal side effects. Always use Exelon exactly as prescribed by your doctor. The dosage is individualized based on tolerability and clinical response. Do not adjust the dose on your own without consulting your healthcare provider.
Adults — Oral Capsules
| Phase | Dose | Duration | Notes |
|---|---|---|---|
| Starting dose | 1.5 mg twice daily | Minimum 2 weeks | Take with morning and evening meals |
| First increase | 3 mg twice daily | Minimum 2 weeks | Increase only if previous dose is well tolerated |
| Second increase | 4.5 mg twice daily | Minimum 2 weeks | Monitor for GI side effects |
| Maximum dose | 6 mg twice daily | Maintenance | 12 mg/day total; highest effective dose |
Exelon capsules should always be taken with food to improve absorption and reduce gastrointestinal side effects. The capsules should be swallowed whole — do not crush, chew, or open them. Taking the medication with the morning and evening meals helps establish a consistent routine and maximizes tolerability.
Adults — Transdermal Patches
| Phase | Patch Strength | Duration | Notes |
|---|---|---|---|
| Starting dose | 4.6 mg/24 hours (5 cm²) | Minimum 4 weeks | Apply one patch daily to clean, dry skin |
| Recommended dose | 9.5 mg/24 hours (10 cm²) | Maintenance | Increase only if well tolerated |
| Maximum dose | 13.3 mg/24 hours (15 cm²) | Maintenance | Only if 9.5 mg/24h is well tolerated and more benefit is expected |
When using transdermal patches, apply only one patch at a time and replace it every 24 hours. Rotate the application site daily (upper arm, upper chest, upper or lower back) and do not apply a new patch to the same area within 14 days. Ensure the skin is clean, dry, and free from lotions, powders, or oils. Press the patch firmly for at least 30 seconds to ensure good adhesion.
Elderly Patients
No specific dose adjustment is required for elderly patients based on age alone. However, as elderly patients are more susceptible to gastrointestinal side effects, dose titration should proceed cautiously with careful monitoring. Patients with low body weight (less than 50 kg) may require slower titration and may not tolerate the highest doses.
Missed Dose
If you miss a dose of Exelon capsules, take the next dose at the regular scheduled time. Do not take a double dose to compensate for a forgotten one. For transdermal patches, if you realize you forgot to apply a patch, apply one immediately and continue with the regular schedule the following day.
If treatment with Exelon (capsules or patches) has been interrupted for more than three consecutive days, do not restart at the previous dose. Contact your doctor immediately. Treatment must be re-initiated at the lowest dose and gradually titrated upward to avoid potentially severe gastrointestinal adverse effects.
Overdose
If you accidentally take more Exelon than prescribed, or if a caregiver accidentally applies more than one patch, remove all patches or stop oral dosing and contact your doctor or emergency services immediately. Symptoms of overdose may include severe nausea, vomiting, diarrhea, excessive salivation, sweating, slow heart rate (bradycardia), low blood pressure, hallucinations, seizures, and muscle weakness. In severe cases, loss of consciousness may occur. Treatment is supportive, and atropine may be administered as an antidote under medical supervision.
What Are the Side Effects of Exelon?
Like all medicines, Exelon can cause side effects, although not everyone experiences them. Side effects are most likely to occur when starting treatment or when the dose is increased. They typically diminish gradually as the body adjusts to the medication. If any side effects become severe or persistent, contact your doctor.
Common
May affect up to 1 in 10 patients
- Nausea
- Vomiting
- Diarrhea
- Loss of appetite
- Heartburn / dyspepsia
- Abdominal pain
- Dizziness
- Headache
- Drowsiness
- Tremor
- Fatigue or weakness
- Weight loss
- Confusion
- Depression
- Anxiety / agitation
- Excessive sweating
- Malaise (general feeling of illness)
- Urinary incontinence
- Urinary tract infection
- Fainting (syncope)
- Rash
- Fever
- Increased salivation
Uncommon
May affect up to 1 in 100 patients
- Cardiac rhythm disturbances (fast or slow heartbeat)
- Stomach ulcers
- Dehydration (fluid loss)
- Hyperactivity / restlessness
- Aggression
- Insomnia (difficulty sleeping)
- Accidental falls
Rare
May affect up to 1 in 1,000 patients
- Seizures (convulsions)
- Falls
- Intestinal ulcers
- Chest pain (angina pectoris)
Very Rare
May affect up to 1 in 10,000 patients
- Extrapyramidal symptoms (muscle stiffness, tremors)
- Pancreatitis (severe upper abdominal pain with nausea/vomiting)
- High blood pressure (hypertension)
- Gastrointestinal bleeding
- Hallucinations
- Esophageal rupture (in cases of severe, prolonged vomiting)
Frequency Not Known
Cannot be estimated from available data
- Worsening of Parkinson's disease symptoms
- Rapid or irregular heartbeat
- Liver function disturbances (jaundice, dark urine, unexplained fatigue)
- Elevated liver enzymes
- Pisa syndrome (involuntary lateral flexion of body and head)
- Nightmares
- Skin rash, itching, redness, blistering
- QTc prolongation
Contact your doctor or seek emergency medical care immediately if you experience: severe allergic reactions (difficulty breathing, swelling of face/throat), signs of pancreatitis (severe upper abdominal pain), seizures, signs of liver problems (yellowing of skin or eyes, very dark urine), severe cardiac symptoms (very slow or very fast heartbeat, fainting), or persistent severe vomiting leading to dehydration.
If you experience gastrointestinal side effects during dose escalation, your doctor may recommend temporarily reducing the dose or maintaining the current dose for a longer period before attempting further increases. In many cases, the body gradually adjusts to the medication and these effects become less troublesome over time.
Adverse drug reactions should be reported to your national pharmacovigilance authority. Reporting suspected adverse reactions helps regulatory agencies continuously monitor the benefit-risk balance of approved medications and detect rare or long-term side effects that may not have been identified during clinical trials.
How Should You Store Exelon?
Proper storage of Exelon is essential to maintain the medication's effectiveness and safety. Follow these guidelines:
- Temperature: Store at or below 25°C (77°F). Do not freeze.
- Packaging: Keep capsules in the original blister packaging. Keep patches sealed in their individual pouches until ready for use.
- Light and moisture: Protect from excessive moisture and direct sunlight.
- Child safety: Store out of sight and reach of children at all times. Used patches still contain active medication and can be dangerous if handled or ingested by children.
- Expiration: Do not use after the expiration date (EXP) printed on the carton and blister/pouch. The expiration date refers to the last day of that month.
Disposal of used patches: After removal, fold the used patch in half with the adhesive side facing inward and press firmly together. Place the used patch back in the original pouch and dispose of it safely out of reach of children. Do not touch your eyes with your fingers after handling the patch, and wash your hands thoroughly with soap and water after removal. If the patch comes into contact with your eyes, rinse immediately with plenty of water and seek medical advice if symptoms persist.
Do not dispose of medications via household waste or wastewater drains. Ask your pharmacist about proper disposal methods for unused or expired medicines. These precautions help protect the environment.
What Does Exelon Contain?
Hard Capsules
Exelon hard capsules contain rivastigmine hydrogen tartrate as the active substance. Each capsule is formulated with the following strengths of rivastigmine (as base):
- 1.5 mg capsule: Contains rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine
- 3 mg capsule: Contains rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine
- 4.5 mg capsule: Contains rivastigmine hydrogen tartrate equivalent to 4.5 mg rivastigmine
- 6 mg capsule: Contains rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine
Transdermal Patches
Exelon transdermal patches are thin, opaque, beige-colored patches that release rivastigmine continuously through the skin over a 24-hour period:
- 4.6 mg/24 hours patch: 5 cm², contains 9 mg rivastigmine
- 9.5 mg/24 hours patch: 10 cm², contains 18 mg rivastigmine
- 13.3 mg/24 hours patch: 15 cm², contains 27 mg rivastigmine
The patches contain additional inactive ingredients including lacquered polyethylene terephthalate film, alpha-tocopherol, poly(butyl methacrylate, methyl methacrylate), acrylic copolymer, silicone oil, dimethicone, and polyester film coated with fluoropolymer.
Exelon is manufactured by Novartis Farmacéutica, S.A. (Barcelona, Spain) and Novartis Pharma GmbH (Nürnberg, Germany), and marketed by Novartis Europharm Limited (Dublin, Ireland). The medication is available in pack sizes of 7, 28, 30, 56, or 112 capsules (depending on the market), and patches are available in packs of 7 or 30 patches.
Frequently Asked Questions About Exelon
Exelon (rivastigmine) is used for the treatment of mild to moderate Alzheimer's dementia in adults. It is a cholinesterase inhibitor that works by increasing acetylcholine levels in the brain, helping to improve memory, thinking, and daily functioning. It is available as oral capsules and transdermal patches. Exelon does not cure Alzheimer's disease but may help manage symptoms and maintain cognitive abilities for a longer period.
The most common side effects of Exelon include nausea, vomiting, diarrhea, loss of appetite, dizziness, headache, drowsiness, and weight loss. These gastrointestinal side effects are most common when starting treatment or increasing the dose and usually improve over time as the body adjusts. Taking the medication with food helps reduce these effects.
Exelon capsules should be taken with food, twice daily (morning and evening). Treatment starts at a low dose of 1.5 mg twice daily and is gradually increased by 1.5 mg per dose at minimum two-week intervals. The maximum recommended dose is 6 mg twice daily (12 mg per day total). Capsules should be swallowed whole and not crushed or chewed.
No, Exelon does not cure Alzheimer's disease. It is a symptomatic treatment that helps manage cognitive symptoms such as memory loss, confusion, and difficulties with daily activities. It works by temporarily boosting acetylcholine levels in the brain, which may slow the progression of symptoms for a period. The underlying neurodegenerative process continues regardless of treatment.
If Exelon treatment has been interrupted for more than three consecutive days, do not restart at your previous dose. Contact your doctor, as the dose will need to be re-titrated from the lowest starting level (1.5 mg twice daily for capsules, or 4.6 mg/24h for patches). This is crucial because restarting at a higher dose after a treatment gap can cause severe gastrointestinal side effects including nausea, vomiting, and diarrhea.
Yes, rivastigmine is available as generic versions from multiple manufacturers including Sandoz, Teva, and STADA. Generic rivastigmine contains the same active ingredient and works identically to brand-name Exelon. Common brand names include Rigmin, Rivastigmine Sandoz, Rivastigmin STADA, Rivastigmine Teva, and Rivastor. Your pharmacist can advise on generic availability in your region.
References
- Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2015;(4):CD001191. doi:10.1002/14651858.CD001191.pub4
- European Medicines Agency (EMA). Exelon — Summary of Product Characteristics. Available at: www.ema.europa.eu
- World Health Organization (WHO). Dementia Fact Sheet. 2023. Available at: www.who.int
- National Institute for Health and Care Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Technology appraisal guidance [TA217]. 2018.
- Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6
- Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J. Effects of transdermal rivastigmine on ADAS-cog items in mild versus moderate Alzheimer's disease. American Journal of Alzheimer's Disease & Other Dementias. 2010;25(8):627-633.
- Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Current Medical Research and Opinion. 2003;19(8):707-714.
- U.S. Food and Drug Administration (FDA). Exelon Prescribing Information. Available at: www.fda.gov
- British National Formulary (BNF). Rivastigmine. Available at: bnf.nice.org.uk
About the Medical Review Team
This article has been medically reviewed by the iMedic Medical Review Board, an independent panel of specialists in neurology, geriatric medicine, and clinical pharmacology. Our editorial process follows international standards for medical content, including the GRADE evidence framework and guidelines from WHO, EMA, AAN, and NICE.
All information is based on peer-reviewed research, systematic reviews, and current clinical practice guidelines. Evidence level 1A wherever applicable.
iMedic receives no commercial funding and maintains complete editorial independence. No pharmaceutical company sponsorship or advertising influences our content.